CTNM Contineum Therapeutics, Inc. Class A Common Stock
USHealthcareAs of 2026-07-10 16:00
Why CTNM matters now
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.19 with -1.68% on the session and $567.9M in market capitalization; recent performance reads 1-month -6.43% and YTD +4.46%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-14.5M, and EPS of $-0.39. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -12.9%.
The latest indexable market news headline is "Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $16.00; recent insider activity includes Lorrain Daniel S. filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.78
P/S
0.00
EV/EBITDA
-7.45
DCF Value
$2.40
FCF Yield
-12.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-27.1%
ROA
-22.4%
ROIC
-26.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-14.5M | $-0.39 |
| Q4 2025 | $0.00 | $-15.2M | $-0.49 |
| FY 2025 | $0.00 | $-60.0M | $-2.17 |
| Q3 2025 | $0.00 | $-12.8M | $-0.45 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$16.00
Target (Median)
$16.00
Target Range
$16.00 - $16.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.89
Contineum Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery and advancement of innovative oral small molecule therapies. Their primary focus lies in addressing neurological, inflammatory, and immunological disorders characterized by significant unmet medical needs. The company's foremost therapeutic candidate is PIPE-791, a pioneering, brain-penetrant small molecule designed to inhibit the lysophosphatidic acid 1 receptor (LPA1R). This compound is currently being investigated for its potential in treating idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). Additionally, Contineum is developing PIPE-307, a novel small molecule functioning as a selective inhibitor of the muscarinic type 1 M1 receptor, intended for the management of depression and relapse-remitting MS. Another asset in their pipeline is CTX-343, an LPA1R antagonist with activity restricted to the periphery. Founded in 2009, this San Diego, California-headquartered organization was formerly known as Pipeline Therapeutics, Inc. before officially changing its name to Contineum Therapeutics, Inc. in November 2023.